Does Thiazolidinedione Therapy Improve Endothelial Function and Preserve Renal Function

• Status: Terminated
• Trial end date: 2009-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The hypothesis of the current proposal is that chronic pioglitazone therapy will result in improved endothelial function, decreased inflammation, and preservation of renal function in patients with CKD but without diabetes.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mayo Clinic
• Treatments: 2,4-thiazolidinedione; Nitroglycerin; Pioglitazone

Criteria

Inclusion Criteria:

• Age over 18 years.

• Creatinine clearance ≤ 60 ml/min by the Cockcroft-Gault equation

• Patients not anticipated to go on dialysis or have renal transplantation in the next 6 months

• Ability to provide informed consent

• Life expectancy greater than 12 months

Exclusion Criteria:

• Diabetes mellitus or a fasting blood glucose ≥ 110 mg/dL

• Acute renal failure

• Class 3 or 4 heart failure

• Liver failure, ascites, or an aspartate aminotransferase (AST) or alanine aminotransferase (ALT) two times the upper limit of normal

• Hemoglobin less than 9 mg/dL

• Multiple myeloma

• Premenopausal women not using at least 1 form of birth control

• Pregnant or nursing women

• Prisoners

• Known allergy to pioglitazone